Abstract
Background: Misoprostol is a synthetic analog of prostaglandin-E1 and it is the most widely used drug for the medical management of incomplete abortion. Acute Coronary Syndrome (ACS) rarely occurs in perimenopausal women, in addition, its presentation is atypical, so the disease is not always recognized.
Case Report: We describe a case of 39-year-old woman with no major underlying cardiovascular risk factors, who developed an episode of ACS following the administration of two doses of misoprostol. After the discontinuation of misoprostol treatment, there was a complete resolution of patient's symptoms. The case draws attention to a rare side effect of a commonly used drug and alerts the clinicians to be cautious in those patients having baseline risk factors which make the patient more susceptible to such serious adverse drug effect.
Keywords: Acute coronary syndrome, misoprostol, prostaglandins, premenopausal women, adverse drug effect, TV-USG.
Current Drug Safety
Title:Misoprostol-induced Acute Coronary Syndrome in a Premenopausal Woman: A Case Report with Literature Review
Volume: 13 Issue: 1
Author(s): Faizan Mazhar*, Jabeen Sultana and Shahzad Akram
Affiliation:
- Department of Basic Medical Sciences, Prince Sultan Military College of Health Sciences, King Fahd Military Medical Complex, Dhahran,Saudi Arabia
Keywords: Acute coronary syndrome, misoprostol, prostaglandins, premenopausal women, adverse drug effect, TV-USG.
Abstract: Background: Misoprostol is a synthetic analog of prostaglandin-E1 and it is the most widely used drug for the medical management of incomplete abortion. Acute Coronary Syndrome (ACS) rarely occurs in perimenopausal women, in addition, its presentation is atypical, so the disease is not always recognized.
Case Report: We describe a case of 39-year-old woman with no major underlying cardiovascular risk factors, who developed an episode of ACS following the administration of two doses of misoprostol. After the discontinuation of misoprostol treatment, there was a complete resolution of patient's symptoms. The case draws attention to a rare side effect of a commonly used drug and alerts the clinicians to be cautious in those patients having baseline risk factors which make the patient more susceptible to such serious adverse drug effect.
Export Options
About this article
Cite this article as:
Mazhar Faizan *, Sultana Jabeen and Akram Shahzad , Misoprostol-induced Acute Coronary Syndrome in a Premenopausal Woman: A Case Report with Literature Review, Current Drug Safety 2018; 13 (1) . https://dx.doi.org/10.2174/1574886312666171122100929
DOI https://dx.doi.org/10.2174/1574886312666171122100929 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Ethnic and Geographical Differences in Ischaemic Stroke Among Young Adults
Current Vascular Pharmacology The Roles of Phosphodiesterase 2 in the Central Nervous and Peripheral Systems
Current Pharmaceutical Design Leukocyte-mediated Tissue Injury in Ischemic Stroke
Current Medicinal Chemistry Interventional Radiology in Paediatrics
Current Pediatric Reviews Update on the Rheumatologic Manifestations of Malignancy
Current Cancer Therapy Reviews Integrin Function and Signaling as Pharmacological Targets in Cardiovascular Diseases and in Cancer
Current Pharmaceutical Design Current Status of Carotid Stenting
Current Vascular Pharmacology Pharmacological Strategies for Inhibition of Thrombin Activity
Current Pharmaceutical Design Thrombolytic Therapy in the Current ERA: Myocardial Infarction and Beyond
Current Pharmaceutical Design New Targets for Anticoagulation and Future Perspectives
Current Drug Discovery Technologies Clinical Evidence and Therapeutic Treatments at the Time of the Coronaviruses Responsible for SARS: A Perspective and Points of view with a Focus on Vascular Endothelium
Coronaviruses Phytocompounds as Potential Agents to Treat Obesity-Cardiovascular Ailments
Cardiovascular & Hematological Agents in Medicinal Chemistry Heart Valve Lesions In The Antiphospholipid Syndrome
Current Rheumatology Reviews Direct Thrombin Inhibitors for Treatment of Heparin Induced Thrombocytopenia, Deep Vein Thrombosis and Atrial Fibrillation
Current Pharmaceutical Design Update on the Therapy of Behçets Disease
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Malignancy and Radiation-Induced Cardiotoxicity
Cardiovascular & Hematological Disorders-Drug Targets Current Management of Neonatal Liver Tumors
Current Pediatric Reviews Anticancer Activity of Selenium Nanoparticles <i>In Vitro</i> Studies
Anti-Cancer Agents in Medicinal Chemistry A Review of Current Treatment Strategies for Varicose Veins
Recent Patents on Cardiovascular Drug Discovery A Review on Molecular Mechanisms and Patents of Marine-derived Anti-thrombotic Agents
Current Drug Targets